Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.50 |
| ▸ | FAAH | O00519 | 1/20 | 0.48 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 6/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.43 |
| ▸ | EED | O75530 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3639598 | 0.88 | MTNR1A (0.59) | AKR1B1MTNR1ATDP1KDM4E | |
| SCHEMBL28031245 | 0.84 | KDM4C (0.46) | KDM4CFAAHMTNR1AALKBH1EED | |
| SCHEMBL6998774 | 0.84 | MTNR1A (0.51) | KDM4CFAAHMTNR1AALKBH1EED | |
| SCHEMBL166877 | 0.83 | KDM4C (0.51) | KDM4CFAAHMTNR1AALKBH1EED | |
| SCHEMBL14665119 | 0.81 | MTNR1A (0.46) | KDM4CFAAHMTNR1AEEDPOLB | |
| SCHEMBL14664161 | 0.80 | MTNR1A (0.44) | KDM4CFAAHMTNR1AEEDPOLB | |
| SCHEMBL95775 | 0.80 | MTNR1A (0.46) | KDM4CFAAHMTNR1AEEDLMNA | |
| SCHEMBL30684116 | 0.79 | AKR1B1 (0.50) | AKR1B1TDP1KDM4EHPGD | |
| SCHEMBL7377233 | 0.78 | KDM4C (0.47) | KDM4CFAAHMTNR1AALKBH1EED | |
| SCHEMBL9160573 | 0.78 | MTNR1A (0.56) | KDM4CFAAHMTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8487121-B2 | Chromane derivatives as TRPV3 modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2013-07-16 | — | — | US | disclosed |
| US-20100311778-A1 | CHROMANE DERIVATIVES AS TRPV3 MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2010-12-09 | — | — | US | disclosed |
| EP-2254879-A2 | CHROMANE DERIVATIVES AS TRPV3 MODULATORS | Glenmark Pharmaceuticals S.A. (CH) | 2010-12-01 | — | — | EP | disclosed |
| WO-2009084034-A2 | CHROMANE DERIVATIVES AS TRPV3 MODULATORS | GLENMARK PHARMACEUTICALS, S. A. (CH) | 2009-07-09 | — | — | WO | disclosed |
| EP-0661271-B1 | AZEPINE DERIVATIVES, PRODUCTION THEREOF, AND USE THEREOF AS SIGMA-RECEPTOR LIGANDS | ASAHI CHEMICAL IND (JP) | 2000-04-26 | — | — | EP | disclosed |
| US-5658923-A | USED IN TREATING DISEASES RELATED TO SIGMA-RECEPTOR, SUCH AS SCHIZOPHRENIA | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1997-08-19 | — | — | US | disclosed |
| EP-0661271-A1 | AZEPINE DERIVATIVE, PRODUCTION THEREOF, AND USE THEREOF | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1995-07-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311778-A1 | CHROMANE DERIVATIVES AS TRPV3 MODULATORS | TRPV3, TRPV2, TRPV1 | KDM4C 3874/4885FAAH 1303/4885AKR1B1 1498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.